Cancer vaccine development: designing tumor cells for greater immunogenicity.
Cancer vaccine development is one of the most hopeful and exhilarating areas in cancer research. For this reason, there has been a growing interest in the development and application of novel immunotherapies for the treatment of cancer with the focus being on stimulating the immune system to target tumor cells specifically while leaving normal cells unharmed. From such research has emerged a host of promising immunotherapies such as dendritic cell-based vaccines, cytokine therapies and gene transfer technology. These therapies seek to counteract the poor immunogenicity of tumors by augmenting the host's immune system with a variety of immunostimulatory proteins such as cytokines and costimulatory molecules. While such therapies have proven effective in the induction of anti-tumor immunity in animal models, they are less than optimal and pose a high risk of clinical infeasibility. Herein, we further discuss these immunotherapies as well as a feasible and efficient alternative that, in pre-clinical animal models, allows for the expression of specific immunostimulatory molecules on the surface of tumor cells by a novel protein transfer technology.
Bozeman
Erica N
EN
Department of Pathology and Laboratory Medicine, Emory University, Atlanta, GA 30322, USA.
Shashidharamurthy
Rangaiah
R
Paulos
Simon A
SA
Palaniappan
Ravi
R
D'Souza
Martin
M
Selvaraj
Periasamy
P
D000818:Animals; D019496:Cancer Vaccines / Q000235:genetics / Q000276:immunology* / Q000627:therapeutic use; D003713:Dendritic Cells / Q000166:cytology / Q000276:immunology; D018014:Gene Transfer Techniques; D006801:Humans; D007109:Immunity / Q000187:drug effects / Q000276:immunology*; D007167:Immunotherapy / Q000379:methods; D008954:Models, Biological; D009369:Neoplasms / Q000276:immunology* / Q000473:pathology / Q000628:therapy; D011993:Recombinant Fusion Proteins / Q000235:genetics / Q000276:immunology
D019496:Cancer Vaccines; D011993:Recombinant Fusion Proteins